-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-01-28
Values as of: 2025-01-28
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
Company Website : www.spdrs.com
Currency: USD
Country : USA
Inception Date: 19/06/2006
Primary Benchmark: S&P Pharms Select Industry TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.35%
Management Expense Ratio: 0.35 %
N/A
N/A
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
-0.86 (-0.59%) |
USD 37.80B |
| FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
-0.36 (-0.52%) |
USD 2.66B |
| FXH | First Trust Health Care AlphaD.. | 0.63 % |
-0.12 (-0.11%) |
USD 1.07B |
| XHE | SPDR® S&P Health Care Equipme.. | 0.35 % |
-0.27 (-0.28%) |
USD 0.21B |
| IDNA | iShares Genomics Immunology an.. | 0.00 % |
-0.17 (-0.75%) |
USD 0.12B |
| SBIO | ALPS Medical Breakthroughs ETF | 0.50 % |
+0.25 (+0.76%) |
USD 0.09B |
| XHS | SPDR® S&P Health Care Service.. | 0.35 % |
-0.41 (-0.40%) |
USD 0.07B |
| HTEC | Robo Global® Healthcare Techn.. | 0.00 % |
-0.40 (-1.29%) |
USD 0.05B |
| BBP | Virtus LifeSci Biotech Product.. | 0.79 % |
-0.38 (-0.61%) |
USD 0.02B |
| BBC | Virtus LifeSci Biotech Clinica.. | 0.79 % |
-0.05 (-0.21%) |
USD 6.89M |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| INAV | 10.31 % | 0.00 % |
N/A |
N/A | |
| MSSS | Northern Lights Fund Trus.. | 10.12 % | 0.00 % |
-0.09 (-0.31%) |
USD 0.11B |
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 5.40% | 38% | F | 80% | B- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 5.40% | 38% | F | 79% | B- | ||
| Trailing 12 Months | |||||||
| Capital Gain | 6.51% | 57% | F | 53% | F | ||
| Dividend Return | 1.60% | 100% | F | 27% | F | ||
| Total Return | 8.11% | 62% | D | 46% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -1.07% | 19% | F | 46% | F | ||
| Dividend Return | 5.61% | 68% | D+ | 15% | F | ||
| Total Return | 4.54% | 24% | F | 31% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -1.72% | 19% | F | 24% | F | ||
| Dividend Return | -0.98% | 19% | F | 16% | F | ||
| Total Return | 0.75% | 68% | D+ | 19% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 15.89% | 67% | D+ | 65% | D | ||
| Risk Adjusted Return | -6.14% | 19% | F | 17% | F | ||
| Market Capitalization | 0.50B | N/A | N/A | N/A | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
